OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

Oxford Biomedica PLC/  GB00BDFBVT43  /

Cboe Europe BXE
9/6/2024  5:21:32 PM Chg. -3.50 Volume Bid5:30:00 PM Ask5:30:00 PM Market Capitalization Dividend Y. P/E Ratio
327.00GBX -1.06% 1,805
Turnover(GBP): 5,891.0350		 -Bid Size: - -Ask Size: - 261.28 mill.GBP - -
GlobeNewswire 9/2 Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today
GlobeNewswire 8/27 Oxford Biomedica to host a free webinar showcasing its AAV expertise
GlobeNewswire 8/8 Aligos Therapeutics Strengthens Board with Two New Independent Directors
GlobeNewswire 8/8 Oxford Biomedica – Half Year Trading Update and Notice of Interim Results
GlobeNewswire 8/6 GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 7/25 Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
GlobeNewswire 7/17 Oxford Biomedica announces CFO transition
GlobeNewswire 4/1 Autolus Therapeutics Announces Changes to its Board of Directors
GlobeNewswire 3/18 Homology Medicines Declares Distribution to Common Stockholders
GlobeNewswire 3/6 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
GlobeNewswire 3/5 Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results
GlobeNewswire 1/29 Oxford Biomedica completes acquisition of ABL Europe
GlobeNewswire 1/23 Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufac...
GlobeNewswire 1/7 Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical ...
GlobeNewswire 1/3 Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
GlobeNewswire 12/7/2023 Business Update
GlobeNewswire 12/4/2023 Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position...
GlobeNewswire 11/16/2023 Q32 Bio and Homology Medicines Announce Merger Agreement
GlobeNewswire 11/14/2023 Homology Medicines Reports Third Quarter 2023 Financial Results
GlobeNewswire 11/9/2023 Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire 9/20/2023 Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed...
GlobeNewswire 9/20/2023 Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
GlobeNewswire 9/7/2023 Oxford Biomedica to host webinar showcasing the TetraVecta™ system
GlobeNewswire 3/23/2022 Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
GlobeNewswire 3/17/2022 Cabaletta Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Upda...